Cellectar Biosciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

NET LOSS PER SHARE (Tables)

NET LOSS PER SHARE (Tables)

9 Months Ended

Sep. 30, 2024

NET LOSS PER SHARE

Schedule of net loss per share


Periods ended September 30, 2024		Three Months			Nine Months
Net loss		$	(14,664,719)		$	(42,226,073)
Dilutive effect of warrant liability			(1,428,355)			(7,283,786)
Net loss allocated to common shares		$	(16,093,074)		$	(49,509,859)

Weighted average common shares outstanding - basic			39,335,924			34,850,441
Dilutive effect of warrant liability			458,296			695,060
Weighted average common shares outstanding - diluted			39,794,220			35,545,500

Net loss per share - diluted		$	(0.40)		$	(1.39)

Schedule of dilutive securities have been excluded from the computation of diluted net loss per share


		Three Months Ended				Nine Months Ended
		September 30,				September 30,
		2024		2023		2024		2023
Warrants		20,412,789		27,148,243		20,412,789		27,148,243
Preferred shares on an as-converted-into-common-stock basis		6,015,662		111,111		6,015,662		111,111
Stock options		5,359,624		2,280,756		5,359,624		2,280,756
Total potentially dilutive shares		31,788,075		29,540,110		31,788,075		29,540,110